These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 11878407

  • 1. Ritonavir/saquinavir plus one nucleoside reverse transcriptase inhibitor (NRTI) versus indinavir plus two NRTIs in protease inhibitor-naive HIV-1-infected adults (IRIS study).
    Florence E, Dreezen C, Desmet P, Smets E, Fransen K, Vandercam B, Pelgrom J, Clumeck N, Colebunder R.
    Antivir Ther; 2001 Dec; 6(4):255-62. PubMed ID: 11878407
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).
    Burger DM, Aarnoutse RE, Dieleman JP, Gyssens IC, Nouwen J, de Marie S, Koopmans PP, Stek M, van der Ende ME.
    Antivir Ther; 2003 Oct; 8(5):455-61. PubMed ID: 14640393
    [Abstract] [Full Text] [Related]

  • 6. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.
    Ananworanich J, Hill A, Siangphoe U, Ruxrungtham K, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Nuesch R, Cooper DA, Hirschel B, Staccato Study Group.
    Antivir Ther; 2005 Oct; 10(6):761-7. PubMed ID: 16218176
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
    Chetchotisakd P, Anunnatsiri S, Mootsikapun P, Kiertiburanakul S, Anekthananon T, Bowonwatanuwong C, Kowadisaiburana B, Supparatpinyo K, Ruxrungtham K, Study Team.
    HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
    [Abstract] [Full Text] [Related]

  • 8. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S, Babacan E, Stephan C, Haberl A, Carlebach A, Gute P, Klauke S, Hermschulte Y, Stuermer M, Dauer B, Frankfurt HIV Cohort.
    J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
    Kirk O, Lundgren JD, Pedersen C, Mathiesen LR, Nielsen H, Katzenstein TL, Obel N, Gerstoft J.
    Antivir Ther; 2003 Dec; 8(6):595-602. PubMed ID: 14760893
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P, ANRS 127 Study Group.
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [Abstract] [Full Text] [Related]

  • 13. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
    Greenberg RN, Feinberg J, Goodrich J, Pilson RS, Siemon-Hryczyk P.
    Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062
    [Abstract] [Full Text] [Related]

  • 14. Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.
    Konopnicki D, De Wit S, Poll B, Crommentuyn K, Huitema A, Clumeck N.
    HIV Med; 2005 Jan; 6(1):1-6. PubMed ID: 15670245
    [Abstract] [Full Text] [Related]

  • 15. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
    Lamotte C, Landman R, Peytavin G, Mentre F, Gerbe J, Brun-Vezinet F, Boue F, Spiridon G, Valantin MA, Michelet C, Farinotti R, Yeni P.
    Antivir Ther; 2004 Apr; 9(2):247-56. PubMed ID: 15134187
    [Abstract] [Full Text] [Related]

  • 16. The danish protease inhibitor study: a randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection.
    Katzenstein TL, Kirk O, Pedersen C, Lundgren JD, Nielsen H, Obel N, Nielsen C, Mathiesen LR, Gerstoft J.
    J Infect Dis; 2000 Sep; 182(3):744-50. PubMed ID: 10950767
    [Abstract] [Full Text] [Related]

  • 17. Failure of double protease inhibitor therapy as a salvage therapy for HIV-infected patients resistant to conventional triple therapy.
    Rockstroh JK, Altfeld M, Kupfer B, Kaiser R, Fätkenheuer G, Salzberger B, Schneweis KE, Spengler U.
    Eur J Med Res; 1999 Jul 28; 4(7):271-4. PubMed ID: 10425264
    [Abstract] [Full Text] [Related]

  • 18. The choice of HIV protease inhibitor: indinavir is currently the best option.
    Prescrire Int; 1999 Apr 28; 8(40):55-60. PubMed ID: 10848067
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.
    Duvivier C, Myrto A, Marcelin AG, Ghosn J, Ait-Mohand H, Schneider L, Agher R, Bricaire F, Costagliola D, Calvez V, Peytavin G, Katlama C.
    Antivir Ther; 2003 Dec 28; 8(6):603-9. PubMed ID: 14760894
    [Abstract] [Full Text] [Related]

  • 20. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
    Mallolas J, Blanco J, Labarga P, Vergara A, Ocampo A, Sarasa M, Arnedo M, López-Púa Y, García J, Juega J, Guelar A, Terrón A, Dalmau D, García I, Zárraga M, Martínez E, Carné X, Pumarola T, Escayola R, Gatell J.
    HIV Med; 2007 May 28; 8(4):226-33. PubMed ID: 17461850
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.